Wu Fanchang, Huang Mingjun, Zuo Xue, Xie Ruiye, Liu Jinman, Ke Junyu, Li Weirong, Wang Qi, Liang Yong
Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China.
Front Pharmacol. 2023 Jul 13;14:1224856. doi: 10.3389/fphar.2023.1224856. eCollection 2023.
Alzheimer's disease (AD) poses a significant threat to the global elderly population. Traditional Chinese medicine (TCM) has been widely utilized in the treatment of AD. Osthole, a bioactive ingredient classified as an "emperor" in many TCM formulas, has been demonstrated to effectively alleviate AD symptoms. However, its low bioavailability in the brain has limited its clinical application. This study aimed to increase the intracerebral bioavailability of osthole by using borneol as a "courier," based on the classical "Emperor-Minister-Assistant-Courier" model, and to investigate the enhanced pharmacological performance of osthole on AD. Results indicated that a suitable thermosensitive gel matrix for intranasal administration mixed with osthole and borneol consists of P407 at 20%, P188 at 7%, and PEG300 at 6%. The concentration of osthole in the cerebrospinal fluid increased almost tenfold after intranasal administration of osthole/borneol compared to oral administration. Mechanisms showed that borneol as a "courier" opened up intercellular space and loosened the tight junctions of the nasal mucosa by suppressing ZO-1 and occludin expression, thereby expediting the nose-to-brain route and guiding osthole as "emperor" to its target in the brain. Osthole assisted by borneol demonstrated significantly improved efficiency in suppressing cleaved caspase-3 expression, increasing the Bcl-2/Bax ratio, improving T-SOD and catalase expression, reducing malondialdehyde levels, inhibiting neuron apoptosis, and decreasing Aβ levels by inhibiting BACE1 expression to alleviate cognitive impairment in APP/PS1 mice compared to osthole alone. Overall, our study demonstrated that the intracerebral bioavailability of osthole profoundly improved with intranasal administration of osthole/borneol and provided a wider application of TCM for AD treatment with higher intracerebral bioavailability.
阿尔茨海默病(AD)对全球老年人口构成重大威胁。传统中药(TCM)已被广泛用于AD的治疗。蛇床子素作为许多中药配方中被归类为“君”的生物活性成分,已被证明能有效缓解AD症状。然而,其在大脑中的低生物利用度限制了其临床应用。本研究旨在基于经典的“君-臣-佐-使”模型,以冰片作为“使”来提高蛇床子素的脑内生物利用度,并研究蛇床子素对AD增强的药理作用。结果表明,一种适合鼻内给药的热敏凝胶基质,与蛇床子素和冰片混合,由20%的P407、7%的P188和6%的PEG300组成。与口服给药相比,鼻内给药蛇床子素/冰片后,脑脊液中蛇床子素的浓度增加了近10倍。机制表明,冰片作为“使”通过抑制ZO-1和闭合蛋白的表达,打开细胞间空间并松弛鼻黏膜的紧密连接,从而加快鼻-脑途径,引导作为“君”的蛇床子素到达其在大脑中的靶点。与单独使用蛇床子素相比,在冰片辅助下的蛇床子素在抑制裂解的caspase-3表达、增加Bcl-2/Bax比值、提高T-SOD和过氧化氢酶表达、降低丙二醛水平、抑制神经元凋亡以及通过抑制BACE1表达降低Aβ水平以减轻APP/PS1小鼠认知障碍方面表现出显著提高的效率。总体而言,我们的研究表明,鼻内给药蛇床子素/冰片可显著提高蛇床子素的脑内生物利用度,并为脑内生物利用度更高的AD治疗提供了更广泛的中药应用。